| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Elizabeth Winan. Aripiprazole. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 60. issue 23. 2004-03-19. PMID:14686220. |
aripiprazole offers an alternative to second-generation antipsychotic agents in the treatment of schizophrenia. |
2004-03-19 |
2023-08-12 |
Not clear |
| James P Kellehe. Aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder. Evidence-based mental health. vol 7. issue 1. 2004-03-01. PMID:14769657. |
aripiprazole is effective against the symptoms of schizophrenia and schizoaffective disorder. |
2004-03-01 |
2023-08-12 |
Not clear |
| Teresa A Pigott, William H Carson, Anutosh R Saha, Anne F Torbeyns, Elyse G Stock, Gary G Ingenit. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of clinical psychiatry. vol 64. issue 9. 2004-02-17. PMID:14628980. |
aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. |
2004-02-17 |
2023-08-12 |
Not clear |
| Teresa A Pigott, William H Carson, Anutosh R Saha, Anne F Torbeyns, Elyse G Stock, Gary G Ingenit. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of clinical psychiatry. vol 64. issue 9. 2004-02-17. PMID:14628980. |
aripiprazole is a novel antipsychotic for the management of schizophrenia. |
2004-02-17 |
2023-08-12 |
Not clear |
| Teresa A Pigott, William H Carson, Anutosh R Saha, Anne F Torbeyns, Elyse G Stock, Gary G Ingenit. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. The Journal of clinical psychiatry. vol 64. issue 9. 2004-02-17. PMID:14628980. |
this study investigated the efficacy, safety, and tolerability of aripiprazole in preventing relapse in adult chronic schizophrenia patients experiencing ongoing stable symptomatology. |
2004-02-17 |
2023-08-12 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research. vol 61. issue 2-3. 2003-12-09. PMID:12729864. |
aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. |
2003-12-09 |
2023-08-12 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research. vol 61. issue 2-3. 2003-12-09. PMID:12729864. |
presented here is a pooled analysis of safety and tolerability data from all completed short-term, placebo-controlled trials in schizophrenia from the aripiprazole clinical development program. |
2003-12-09 |
2023-08-12 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research. vol 61. issue 2-3. 2003-12-09. PMID:12729864. |
data were analyzed from five 4- to 6-week double-blind multicenter studies of patients hospitalized with acute relapse of schizophrenia or schizoaffective disorder randomized to aripiprazole (n=932), placebo (n=416), or haloperidol (n=201). |
2003-12-09 |
2023-08-12 |
Not clear |
| Stephen R Marder, Robert D McQuade, Elyse Stock, Stephen Kaplita, Ronald Marcus, Allan Z Safferman, Anutosh Saha, Mirza Ali, Taro Iwamot. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophrenia research. vol 61. issue 2-3. 2003-12-09. PMID:12729864. |
aripiprazole's safety profile may offer benefits in schizophrenia treatment. |
2003-12-09 |
2023-08-12 |
Not clear |
| Martha Sajatovi. Treatment for mood and anxiety disorders: quetiapine and aripiprazole. Current psychiatry reports. vol 5. issue 4. 2003-12-09. PMID:12857536. |
aripiprazole was recently approved for the treatment of schizophrenia by the us food and drug administration in late 2002, and is being used increasingly in clinical settings. |
2003-12-09 |
2023-08-12 |
Not clear |
| Steven G Potkin, Anutosh R Saha, Mary J Kujawa, William H Carson, Mirza Ali, Elyse Stock, Joseph Stringfellow, Gary Ingenito, Stephen R Marde. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of general psychiatry. vol 60. issue 7. 2003-09-16. PMID:12860772. |
aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. |
2003-09-16 |
2023-08-12 |
Not clear |
| Steven G Potkin, Anutosh R Saha, Mary J Kujawa, William H Carson, Mirza Ali, Elyse Stock, Joseph Stringfellow, Gary Ingenito, Stephen R Marde. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Archives of general psychiatry. vol 60. issue 7. 2003-09-16. PMID:12860772. |
this multicenter trial examined the efficacy, safety, and tolerability of aripiprazole in patients with acute exacerbation of schizophrenia or schizoaffective disorder. |
2003-09-16 |
2023-08-12 |
Not clear |
| W W Fleischhacke. New developments in the pharmacotherapy of schizophrenia. Journal of neural transmission. Supplementum. issue 64. 2003-08-06. PMID:12830932. |
while the concept of partial d1-agonism has already led to the successful launch of a new antipsychotic, aripiprazole, the other attempts to improve therapeutic response in schizophrenia patients have so far provided equivocal results. |
2003-08-06 |
2023-08-12 |
Not clear |
| Toya M Bowles, Gary M Levi. Aripiprazole: a new atypical antipsychotic drug. The Annals of pharmacotherapy. vol 37. issue 5. 2003-06-23. PMID:12708948. |
to review the pharmacology, pharmacokinetics, clinical efficacy, and safety profile of aripiprazole for the treatment of schizophrenia. |
2003-06-23 |
2023-08-12 |
Not clear |
| D M Taylo. Aripiprazole: a review of its pharmacology and clinical use. International journal of clinical practice. vol 57. issue 1. 2003-05-19. PMID:12587943. |
once-daily aripiprazole 15-30 mg is as effective as haloperidol 10 mg/day and risperidone 6 mg/day in short-term treatment of schizophrenia and more effective than haloperidol 7-10 mg/day in maintenance of response in chronic schizophrenia. |
2003-05-19 |
2023-08-12 |
Not clear |
| Jane K McGavin, Karen L Go. Aripiprazole. CNS drugs. vol 16. issue 11. 2003-04-04. PMID:12383035. |
in patients with acute relapse of schizophrenia or schizoaffective disorder, aripiprazole 15 to 30 mg/day was at least as effective as haloperidol 10 mg/day and had similar efficacy to risperidone 6 mg/day in well designed, 4-week, placebo-controlled trials. |
2003-04-04 |
2023-08-12 |
Not clear |
| Jane K McGavin, Karen L Go. Aripiprazole. CNS drugs. vol 16. issue 11. 2003-04-04. PMID:12383035. |
aripiprazole was superior to placebo in a 26-week trial in patients with stable, chronic schizophrenia. |
2003-04-04 |
2023-08-12 |
Not clear |
| Aripiprazole (Abilify) for schizophrenia. The Medical letter on drugs and therapeutics. vol 45. issue 1150. 2003-03-20. PMID:12592215. |
aripiprazole (abilify) for schizophrenia. |
2003-03-20 |
2023-08-12 |
Not clear |
| Vural Ozdemir, Jeanne Fourie, Fatih Ozdene. Aripiprazole (Otsuka Pharmaceutical Co). Current opinion in investigational drugs (London, England : 2000). vol 3. issue 1. 2002-12-17. PMID:12054061. |
otsuka pharmaceuticals in collaboration with bristol-myers squibb is developing aripiprazole, a dual dopamine autoreceptor agonist and postsynaptic d2 receptor antagonist, for the potential treatment of psychoses including schizophrenia [281327], [340364]. |
2002-12-17 |
2023-08-12 |
Not clear |
| Vural Ozdemir, Jeanne Fourie, Fatih Ozdene. Aripiprazole (Otsuka Pharmaceutical Co). Current opinion in investigational drugs (London, England : 2000). vol 3. issue 1. 2002-12-17. PMID:12054061. |
moreover, the mechanism of action of aripiprazole differentiates it from both typical and atypical antipsychotics and hence, may provide important leads for pharmacotherapy of schizophrenia and other psychotic disorders. |
2002-12-17 |
2023-08-12 |
Not clear |